KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma

Journal of Pathology

Volumn 231, Issue 4, 2013, Pages 449-456

  Tsang, Yvonne T ^a   Deavers, Michael T ^a   Sun, Charlotte C ^a   Kwan, Suet Yan ^a,b   Kuo, Eric ^a   Malpica, Anais ^a   Mok, Samuel C ^a   Gershenson, David M ^a   Wong, Kwong Kwok ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

BRAF; COLD PCR; deep sequencing; KRAS; mutation; ovarian low grade serous carcinoma; serous borderline tumour

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PARAFFIN; SELUMETINIB;

ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISSECTION; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARIAN LOW GRADE SEROUS CARCINOMA; OVARIAN SEROUS BORDERLINE TUMOR; OVARY CARCINOMA; OVARY TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DENATURATION; RECURRENT CANCER; SENSITIVITY ANALYSIS; SURVIVAL TIME; TEMPERATURE; WILD TYPE;

BRAF; COLD-PCR; DEEP SEQUENCING; KRAS; MUTATION; OVARIAN LOW-GRADE SEROUS CARCINOMA; SEROUS BORDERLINE TUMOUR;

ADULT; AGED; BENZIMIDAZOLES; CELL DEATH; CYSTADENOCARCINOMA, SEROUS; CYSTADENOMA, SEROUS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KAPLAN-MEIER ESTIMATE; MAP KINASE KINASE KINASES; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84887534434     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4252     Document Type: Article

References (41)

1. Wong KK, Gershenson D,. The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary. Dis Markers 2007; 23: 377-387.
2. Vang R, Shih IeM, Kurman RJ,. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009; 16: 267-282.
3. Diaz-Padilla I, Malpica AL, Minig L, et al., Ovarian low-grade serous carcinoma a comprehensive update. Gynecol Oncol 2012; 126: 279-285.
4. McCluggage WG,. The pathology of and controversial aspects of ovarian borderline tumours. Curr Opin Oncol 2010; 22: 462-472.
5. Bonome T, Lee JY, Park DC, et al., Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005; 65: 10602-10612.
6. Shih IeM, Chen L, Wang CC, et al., Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am J Obstet Gynecol 2010; 203: 584.e1-584.e22.
7. Tung CS, Mok SC, Tsang YT, et al., PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol 2009; 22: 1243-1250.
8. Crispens MA, Bodurka D, Deavers M, et al., Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 2002; 99: 3-10.
9. Shvartsman HS, Sun CC, Bodurka DC, et al., Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol 2007; 105: 625-629.
10. Jones MB,. Borderline ovarian tumors: current concepts for prognostic factors and clinical management. Clin Obstet Gynecol 2006; 49: 517-525.
11. Shih KK, Zhou Q, Huh J, et al., Risk factors for recurrence of ovarian borderline tumors. Gynecol Oncol 2011; 120: 480-484.
12. Gershenson DM,. Contemporary treatment of borderline ovarian tumors. Cancer Invest 1999; 17: 206-210.
13. Gilks CB, Alkushi A, Yue JJ, et al., Advanced-stage serous borderline tumors of the ovary a clinicopathological study of 49 cases. Int J Gynecol Pathol 2003; 22: 29-36.
14. Longacre TA, McKenney JK, Tazelaar HD, et al., Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 2005; 29: 707-723.
15. Silva EG, Gershenson DM, Malpica A, et al., The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol 2006; 30: 1367-1371.
16. Shih IeM, Kurman RJ., Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 2005; 11: 7273-7279.
17. Auersperg N., Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis? Gynecol Oncol 2013; 130: 246-251.
18. Vang R, Shih IeM, Kurman RJ,. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 2013; 62: 44-58.
19. Kuo KT, Guan B, Feng Y, et al., Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 2009; 69: 4036-4042.
20. Wong KK, Tsang YT, Deavers MT, et al., BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol 2010; 177: 1611-1617.
21. Hsu CY, Bristow R, Cha MS, et al., Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 2004; 10: 6432-6436.
22. Mok SC, Bell DA, Knapp RC, et al., Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993; 53: 1489-1492.
23. Singer G, Oldt R 3rd, Cohen Y, et al., Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95: 484-486.
24. Mayr D, Hirschmann A, Lohrs U, et al., KRAS and BRAF mutations in ovarian tumors a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006; 103: 883-887.
25. Grisham RN, Iyer G, Garg K, et al., BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2013; 119: 548-554.
26. Farley J, Brady WE, Vathipadiekal V, et al., Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 2013; 14: 134-140.
27. Altman AD, Nelson GS, Ghatage P, et al., The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. Mod Pathol 2013; 26: 1255-1263.
28. Jones S, Wang TL, Kurman RJ, et al., Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 2012; 226: 413-420.
29. Thomas RK, Nickerson E, Simons JF, et al., Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nature Med 2006; 12: 852-855.
30. Milbury CA, Li J, Makrigiorgos GM,. COLD-PCR-enhanced high-resolution melting enables rapid and selective identification of low-level unknown mutations. Clin Chem 2009; 55: 2130-2143.
31. Barretina J, Caponigro G, Stransky N, et al., The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
32. Reva B, Antipin Y, Sander C,. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 2011; 39: e118.
33. Shepherd R, Forbes SA, Beare D, et al., Data mining using the Catalogue of Somatic Mutations in Cancer BioMart. Database (Oxford) 2011; 2011: bar018.
34. Gabriel S, Ziaugra L, Tabbaa D,. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet 2009; 60: 2.12.1-2.12.18.
35. Andreyev HJ, Norman AR, Cunningham D, et al., Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85: 692-696.
36. Keohavong P, DeMichele MA, Melacrinos AC, et al., Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res 1996; 2: 411-418.
37. Monticone M, Biollo E, Maffei M, et al., Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context. Mol Cancer 2008; 7: 92.
38. Al-Mulla F, MacKenzie EM,. Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations. J Pathol 2001; 195: 549-556.
39. Cerami E, Gao J, Dogrusoz U, et al., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-404.
40. Dehari R, Kurman RJ, Logani S, et al., The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma a morphologic and molecular genetic analysis. Am J Surg Pathol 2007; 31: 1007-1012.
41. Parker RL, Clement PB, Chercover DJ, et al., Early recurrence of ovarian serous borderline tumor as high-grade carcinoma a report of two cases. Int J Gynecol Pathol 2004; 23: 265-272.